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Resumen
Orlistat induce la pérdida de peso mediante el bloqueo de la hidrólisis de triglicéridos en el intestino, por lo que también se asocia con cambios 
favorables en los triglicéridos posprandiales (PHTGL). Algunos estudios epidemiológicos han identificado concentraciones PHTGL como un 
importante factor de riesgo para la enfermedad cardiovascular. El test de sobrecarga oral de grasa (TSOG) se ha utilizado para la detección de 
niveles elevados de PHTGL. El objetivo de la presente revisión sistemática es presentar los datos disponibles sobre los efectos de orlistat en TSOG.
Encontramos 11 estudios, de los cuales 7 estudian el efecto de una sola dosis de orlistat en el TSOG: 3 con voluntarios sanos, 1 con obesidad, 
2 con diabetes de tipo 2 y 1 con pacientes hiperlipidémicos. Los otros 4 estudian también el efecto de orlistat en el TSOG, pero después de un 
periodo de tiempo previo con un tratamiento diario con orlistat: 1 con voluntarios sanos, 2 con obesidad y 1 con un paciente con hiperlipidemia.
Nuestra revisión sistemática sugiere que orlistat puede ayudar a reducir la hipertrigliceridemia posprandial en pacientes obesos, dislipémicos y 
con diabetes de tipo 2. Respecto a los ácidos grasos libres plasmáticos, también los podría reducir, pero no todos los autores han encontrado los 
mismos resultados. En pacientes diabéticos de tipo 2 se han encontrado tres estudios con resultados contradictorios sobre el efecto inmediato 
de orlistat en la respuesta postprandial de GLP-1.
En conclusión, orlistat puede ayudar a reducir los TGL plasmáticos posprandiales, especialmente en pacientes con hipertrigliceridemia posprandial 
relacionada con obesidad, dislipemia y diabetes de tipo 2.
Abstract
Orlistat induces weight loss by blocking hydrolysis of triglyceride in the intestine, and has thereby been associated with favorable changes in 
postprandial triglycerides (ppTGL). Some epidemiological studies have identified ppTGL concentrations as a significant risk factor for cardiovascular 
disease. Oral fat loading test (OFLT) has been used for screening of elevated levels of ppTGL. The objective of the present systematic review is 
to present available data on the effects of orlistat on OFLT.
We found 11 studies, seven of which studied the effect of a single dose of orlistat on OFLT in three healthy volunteers, one with obesity, two with 
type-2 diabetes and one with hyperlipidemic patients. The other four studied the effect of orlistat on OFLT, but after a previous period of time with 
daily treatment with orlistat: 1 healthy volunteer, 2 obese volunteers, and one patient with hyperlipidemia.
Our systematic review suggests that orlistat can help to reduce postprandial hypertriglyceridemia in obese, dyslipemic and type-2 diabetic patients. 
Regarding free fatty acids, they could be reduced but not all the authors have found the same results. In relation to type-2 diabetic patients, we 
have found three studies with conflicting results on the immediate effect of orlistat on the postprandial GLP-1 response.
In conclusion, orlistat can help to reduce postprandial plasmatic TGL, especially in patients with postprandial hypertriglyceridemia related to 
obesity, dyslipidemia or type-2 diabetes.
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INTRODUCTION
Humans consume regular meals during the day; therefore, we 
are in a dynamic state of continuous changes in postprandial 
lipid and lipoprotein metabolism. Postprandial lipemia is a normal 
physiological phenomenon that usually lasts from 6 to 8 hours 
after ingestion of a fatty meal. However, postprandial hypertri-
glyceridemia (PHTGL) is an exaggerated magnitude and duration 
of triglyceride (TGL) response after a fatty meal, which results in 
the accumulation of TGL and their remnants in the circulation.
The causes of PHTGL include: decreased hepatic receptor 
activity, defect in the ligand for these receptors, impaired lipolysis 
by lipoprotein lipase (LPL) and Apo C (Apolipoprotein C) dysreg-
ulation by acting as an inhibitor of LPL and TGL remnant uptake 
by hepatic lipoprotein receptors (1). 
The atherogenicity of TGL relates to the smaller remnant parti-
cles that readily infiltrate the subendothelial space of the arterial 
wall. These TGL remnants are phagocytized by arterial wall mac-
rophages, which then transform into foam cells, impair endothelial 
function, active monocytes and inflammatory signaling pathways, 
and also have a direct effect on thrombogenicity (2,3). 
Some epidemiological studies have identified non-fasting TGL 
concentrations as a significant risk factor for cardiovascular dis-
ease. Copenhagen City Heart study (4), Women’s Health study (5) 
and the Norwegian Counties study (6), all found highly significant 
associations between cardiovascular events with increases in 
non-fasting TGL.
Furthermore, the findings in the 31st year follow-up of Copen-
hagen City Heart study (4) were in agreement with its previous 
data, with non-fasting TGL being similarly associated with an 
increased risk of myocardial infarction, ischemic heart disease (7), 
and ischemic stroke (8). In addition, there is a meta-analysis of 
101 studies suggesting the causal role of plasma TGL in coronary 
disease (9). 
The role of TGL has been emphasized by recent major guide-
lines. A therapeutic fasting target level of triglyceride of less than 
150 mg/dL is recommended in higher-risk patients, especially 
those with diabetes and metabolic syndrome (10,11).
Non-fasting TGL cutoff levels of ≥ 180 mg/dL and > 220 mg/dl 
after the Oral Fat Loading Test (OFLT) have been used for screen-
ing and management of elevated TGL levels (12).
Dietary and lifestyle modifications remain the cornerstone of 
therapeutical management, whose function is to lower plasmatic 
TGL, and this is the first-step approach. Subsequent steps are 
pharmacotherapies including fibrates, niacin (currently not avail-
able in Spain), and n-3 fatty acids. 
New therapies, such as dual peroxisome-proliferator-activated 
receptor α/δ agonists, diacylglycerol, inhibitors of diacylglycerol acyl-
transferases-1, microsomal triglyceride transfer protein, antisense 
oligonucleotides for apoB-100 and apoC-III, and incretin-based ther-
apies could be also employed to optimize the treatment. 
Orlistat is a drug approved in the year 1999 for long-term 
weight loss in adults. Orlistat induces weight loss by blocking 
the hydrolysis of triglyceride in the stomach and small intestine, 
thereby, inhibiting absorption of approximately 30% of dietary fat.
Anti-obesity drugs help to reduce body weight, thus, contribut-
ing to an improvement in cardiovascular risk factors. However, the 
direct effect of anti-obesity drugs on cardiovascular risk factors 
is unclear (13). Orlistat not only induced weight loss, but it was 
also associated with favorable changes in lipids, fasting glucose, 
and blood pressure. The Orlistat Swedish Multi-morbidity Study 
showed greater improvement in coronary risk factors with orlistat 
than with diet changes alone in obese patients with hypertension, 
hypercholesterolemia, and/or type 2 diabetes (14). These results 
have been observed in other studies (15). More so, the metabolic 
effects of orlistat are not only limited to cardiovascular risk factors, 
but also to a lower incidence of type 2 diabetes (16).
Orlistat may represent a pharmacological approach to cardio-
vascular risk modulation in overweight/obese patients, although 
no agency has admitted that indication. The objective of the ongo-
ing systematic review is to present available data on the effects 
of orlistat on OFLT. 
METHODS
SEARCH STRATEGY
A literature search has been made in the following medical 
databases through June 2015: Medline (PubMed), Embase, 
Cochrane Library and Trip Database. National and international 
agencies like the CRD (Centre for Reviews and Dissemination), 
NICE (National Institute for Health and Care Excellence), HEN 
(Health Evidence Network) , IQWIG (Institute for Quality and Effi-
ciency in Health Care), INAHTA (International Network of Agencies 
for Health Technology Assessment), EuroScan, NHSC (NIHR Hori-
zon Scanning Centre), AHRQ (Agency for Healthcare Research and 
Quality), CEDIT (Comité d’évaluation des technologies de santé), 
CADTH (Canadian Agency for Drugs and Technologies in Health), 
UKMI (United Kingdom Medicines Information, NHS), EMEA (Euro-
pean Medicines Agency), AEMPS (Spanish Agency for Medicines 
and Health Products), AETS-ISCIII (Agency for Health Technology 
Assessment of the Institute Carlos III, Spain), OSTEBA (Service 
Health Technology Assessment of the Basque Country), AETSA 
(Agency for Health Technology Assessment Andalusia) were also 
revised. 
The literature search in medical databases followed these steps:
1.  “Hyperlipidemias” [mesh] and “Postprandial period” [mesh]. 
2.  Postprandial lipemia [title/abstract] OR postprandial lipid 
[title/abstract] or postprandial hypertriglyceridemia [title/
abstract] OR postprandial triglyceride [title/abstract] OR 
postprandial triglycerides [title/abstract] OR postprandial 
lipaemia [title/abstract] OR postprandial hyperlipidemia 
[title/abstract] OR oral lipid tolerance test [title/abstract] OR 
postprandial [title/abstract].
3.  #1 OR #2.
4.  “Orlistat” [supplementary concept].
5.  Xenical [title/abstract] OR orlistat [title/abstract].
6.  #4 OR #5.
7  #3 AND #6.
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A filter for studies in humans was also used. The search was 
restricted to articles in English and Spanish languages. The search 
was refined by eliminating duplicate documents.
The retrieved studies were manually screened to assess their 
appropriateness for inclusion. Bibliographies of all identified trials 
and review articles were reviewed to look for additional studies 
of interest. 
An investigator reviewed all the citations retrieved from the 
electronic search in order to identify relevant articles for this 
review. Other investigators subsequently reviewed the selection, 
to determine eligibility.
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria: Studies with healthy, cardiovascular or metabol-
ic disease participants, regardless of their body mass index (BMI), 
their age (> 18 years), with no chronic medication, who underwent 
an OFLT were included.
Exclusion criteria: Reports, editorials and review articles were 
excluded. 
DATA EXTRACTION AND QUALITY 
EVALUATION
All articles provided measures for blood determinations, including 
mean and standard deviation (SD) or standard error of the mean (SEM), 
at least at baseline and at one other postprandial time point.
The following data were abstracted in tables onto the stand-
ardized case report forms: authors; year of publication; number 
of patients, sex, age, BMI and characteristics of the treatment 
and control groups (healthy, obese, hyperlipidemia, metabolic syn-
drome or diabetes); study goals; methods of randomization and 
blinding; duration and characteristics of treatment; administered 
fat load test; outcomes; and adverse event data.
A validated 3-item scale was used to assess the overall 
reporting quality of the selected studies for inclusion in the pres-
ent review (17). This scale provides scoring for randomization 
(0-2 points), double-blinding (0-2 points), and account for with-
drawals (1 point). Scores ranged between 0 and 5, and scores ≥ 3 
indicate a high quality study.
RESULTS
A total of 78 citations were identified by the systematic liter-
ature search (66 from medical databases and 12 from national 
and international agencies), 49 of which were deemed potentially 
eligible. 38 of the 49 articles were excluded because they did not 
meet the inclusion criteria. Thus, a total of 11 trials were eligible 
for analysis (18-28), only 7 of which were double-blind rand-
omized controlled trials (RCT) (18,19,22-26) (Fig. 1).
A total of 7 papers (18-24) studied the effect of a single dose of 
orlistat on OFLT (Table I), 3 of which were carried out with healthy 
volunteers (18-20), 1 with obese patients (21), 2 with type 2 
diabetes patients (22,23), and 1 with hyperlipidemic patients (24).
Of the total 11 included studies, only 4 studied the effect of 
orlistat on postprandial lipemia, after a period of time with a daily 
treatment using orlistat (24-28) (Table II). Among these, 1 was 
carried out with healthy volunteers (25), 2 with obese (26,27), 
and 1 with hyperlipidemic patients (24).
Only one study conducted an OFLT after 8 weeks of orlistat 
treatment and a second OFLT after two weeks of placebo (24), so 
it is included in all tables.
STUDY CHARACTERISTICS
The characteristics of the included studies are listed in tables I 
and II, and summarized in tables III and IV. 
There are two studies that are not randomized or blinded 
(20,21), but they were included due to the number of patients. 
The dose of fat used in the OFLT was variable, with about 
Figure 1. 
Flow diagram for identification, screening, eligibility and inclusion of articles in 
our systematic review.
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Table I. Characteristics of studies with single dose of orlistat
Author Patients Methodology
Orlistat 
administration
Results with orlistat
Sutter (18)
10 healthy young men
BMI 21.5 ± 1.2 kg/m2
Age 25 ± 3 years
Double-blind, randomized, crossover 
study.
Postprandial TGL 8 h AUC was 
determined on 3 separate days. 
Each test meal contained either 1 g 
(high fat) or 0.67 g (moderate-fat) of fat 
per kg body weight
Single-dose orlistat 
120 mg plus a high-fat 
meal or moderate fat 
meal, or placebo plus high 
fat meal
Orlistat leads to: 
1. Lower postprandial TGL 
response and significant 
reduction in the AUC-TGL
2. VLDL size was significantly 
smaller
3. Decrease in small HDL 
particle concentration and 
increase in intermediate HDL
Gabriel (19)
31 healthy volunteers
BMI 18.5-23.5
Age range of 18 to 
45 years
Male and female
Normal fasting lipids
Blindly randomized study
High fat meal: 50% fat meals 
Lipid level determination at 0, 4, 5 and 
9 h
Receive either placebo 
or orlistat 120 mg before 
each main meal during 
one day
TGL, VLDL; LDL and TC for 
orlistat
group was lower than placebo 
group
Abejuela (20)
27 healthy volunteers
BMI 18.5-22.9 kg/m2
Age range of 18-45 years
Normal fasting lipid levels
No blindly randomized study
50% oral fat challenge test
Plasma lipid was determined at 0, 1, 2, 
3, 4, 5 and 6 h
15 volunteers receive 
orlistat 120 mg and 
12 volunteers none before 
oral fat challenge test
Lipid peaking was not observed 
in the orlistat group
Cintora (21)
33 overweight/obese 
patients. BMI: 31.4 + 44
Age: 44.3 ± 9.9 years
No blindly randomized study 
Postprandial measurements of TGL 
and HDL-c were performed at 4 and 
8 h after food intake on both days. 
Composition of the test meal: 53 g lipid
Two-days study: 
standardized, fat-
containing meal on day 1 
and the same meal plus a 
single oral dose of orlistat 
(120 mg) on day 2
The addition of orlistat reduced:
1-the value peak plasma 
concentration of TG (at 4 h but 
not at 8am)
2-TGL-AUC by 54.9%
Tan (22)
63 overweight patients 
with T2DM
BMI: 30.4 ± 3.8
Age: 45.2 ± 10.7
Randomized, double blind, placebo-
controlled cross-over study
The test meal contained 70 g of fat
Blood samples were collected at 
baseline before the test meal and then 
at 2 h intervals for 8 h
Either a single dose 
of orlistat 120 mg or 
placebo was given before 
a standard mixed meal
The concentrations of plasma 
TGL, RLP-C, and FFA were 
significantly lower at 2 h after 
orlistat compared with placebo
Damci (23)
29 T2DM patients, who 
were not taking insulin or 
alfa glucosidase inhibitors
BMI: 31.0 ± 4.1
Age: 54.9 ± 10.4 years
Crossover randomized and single-blind 
design
At baseline and 60 min after the meal, 
blood samples were obtained
Standard 600-kcal mixed meal that 
contained 38% fat (25 g)
A single dose 120 mg 
orlistat or placebo 
capsules
The orlistat administration 
enhanced postprandial increase 
in GLP-1 and C-peptide levels 
and attenuated the postprandial 
rise in glucose and TGL
Reitsma (24)
17 hyperlipidemic 
subjects: fasting plasma 
CT > 6.2 mmol/l and TGL 
> 5 mmol/l, 
BMI: 24.8 ± 3.4 kg/m2 
Age: 55.0 ± 2 6.9
Multicenter double-blind, randomized
Test meal: 50 g fat/m2 on the last day 
of 8 weeks treatment period and after 
2 weeks placebo period
Peripheral blood samples: before and at 
2-hour intervals after test meal
First oral load test: 
placebo or orlistat doses 
from 8 weeks treatment 
period
Second oral load test: a 
single dose of of orlistat 
120 mg or placebo after 
2-week follow-up period 
on placebo  
(weeks 8 to 10)
Reductions of TC, LDL, and apo 
B levels with 8 weeks orlistat 
treatment
Postprandial TGL was 
decreased by 27% Changes in 
the TGL AUC were associated 
with changes in the RP AUC 
and decreased levels in LDL 
cholesterol
BMI: Body mass index; TC: Total cholesterol; TGL: Triglyceride; LDL: Low density lipoproteins; HDL: High density lipoproteins; VLDL: Very low density lipoproteins, retinyl 
palmitate (RP); AUC: Area under the curve; T2DM: Type 2 diabetes mellitus; RLP-C: Remnant-like particles cholesterol; GLP-1: Glucagon-like peptide 1.
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28 grams (25) to 60 grams per square meter of body surface 
(27). In many studies, the exact dose of fat used is not clearly 
defined. In this regard, studies are not comparable. Howev-
er, the dose of Orlisat used was always 120 mg, as a single 
dose or in short treatment (before breakfast, lunch and dinner). 
In most studies, TGL area under the curve (AUC) was calculated. 
Meta-analysis was not considered because test meals, duration 
of observation in the postprandial state, and the type of patients 
differ within the study.
HEALTHY VOLUNTEERS
We found that 3 studies were done with a single dose of orlistat 
in healthy volunteers (18-20), which make up 68 individuals in all. 
The response to the OFLT was homogeneous in all patients 
with a reduced postprandial triglyceride AUC compared to pla-
cebo. In addition, a significant reduction of total LDL cholesterol 
levels (19,20), HDL cholesterol (18,20) and VLDL (18,19) was 
observed.
Table II. Characteristics of studies after sort treatment of orlistat
Author Patients Methodology
Orlistat 
administration
Results with orlistat
Shepard (25)
24 healthy male
In placebo group: 
Age: 31 ± 2 y 
BMI: 25.1 ± 0.5 
In orlistat group: 
Age: 35 ± 2 years
BMI: 26.8 ± 1.0
Double-blind, randomized, 
parallel group, placebo-
controlled study
Fat rich breakfast (830 Kcal 
and 28 g fat) and single dose 
of orlistat or placebo
Determinations were made 
prior to breakfast and then 
hourly over 12 h, in day 0 
and days 5 and 10 
Orlistat 120 mg 
or placebo three 
times per day during 
10 days
Meal test plus single 
dose of orlistat or 
placebo on days 
5 and 10 was 
performed
There were no treatment differences in 
peak TGL response and AUC for any of 
the postprandial lipids or lipoproteins, 
including TGL, LDL and VLDL
The inhibitory effect of orlistat on lipase is 
limited to the gastrointesinal tract and is 
not manifested systemically
Di Somma (26)
22 healthy 
postmenopausal 
women with obesity 
class I-II
BMI: 34.1 ± 4.0 
Age: 53.6 ± 6.2
Randomized, simple-blind, 
cross-over study
At the end of 10 day 
treatment period was 
performed postprandial test. 
Determinations at 0, 2, 4, 
6 and 8 h. Meal provided 
944 Kcal and 57% fat
Standard mixed meal 
(944 Kcal and 60 g fat) 
120 mg after meals 
or placebo during 
10 days plus normo-
caloric diet
Orlistat induced a weight independent 
reduction in postprandial NEFA associated 
with an improvement in GH/IGF-I status
Turker (27)
26 normolipemic obese 
female with PPL
Prospective, randomized, no 
blind study
A meal contained 60 g/m2 fat 
and 1,800 Kcal with 64% of 
total calories from fat
Determination of serum lipids 
0,2,4,6 and 8 h 
One group with diet 
and orlistat 120 mg 
3 times/day and 
other group only diet, 
during 12 weeks
Reduction in TGL
Related to fasting TGL, insulin and HOMA 
at 12 weeks
Tzotzas (28)
32 obese, non-diabetic 
women with metabolic 
syndrome
Age: 50.1 ± 8.2 years
Prospective, randomized, no 
blind study
Capillary triglycerides (TGc) 
were measured at 6 different 
time points during the day
Daytime triglyceridemia was 
expressed as area under the 
curve of TGc (AUC-TGc)
Low-calorie diet: 1,480 ± 
45 kcal/day
Fat 29.5%
2 similar groups: G1 
with a low-calorie 
diet combined with 
orlistat 120 mg tid 
for 10 days and G2 
(control), with only the 
low-calorie diet
Following minimal weight loss, AUC 
capillary TGL decreased by 17%. It was 
significantly correlated with the decrease 
of HOMA index
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Regarding the response of postprandial free fatty acids (FFA), 
glucose and insulin, only one study explored this (18), with no 
significant results.
After 10 days of treatment with orlistat, Shepard et al. (25), 
in an article of high methodological quality, found no signifi-
cant difference regarding the postprandial response with orl-
istat compared to placebo in any of the previously mentioned 
parameters.
NORMOLIPEMIC OBESE POST MENOPAUSE 
FEMALE
We have found only two articles with normolipemic obese post 
menopause female.
Cintora et al. (21) conducted an OFLT with orlistat and observed 
an attenuation of the AUC and peak of TGL at 4 hours.
Later, Di Somma et al. (26) performed an OFLT after 10 days of 
daily treatment with orlistat. The result showed lower postprandial 
response in the treatment group in total cholesterol, LDL choles-
terol, HDL cholesterol, FFA and insulin, but not in TGL.
DISLIPEMIA
We have found three papers with different types of dyslipi-
demia: obese with only PPL (27), obese with metabolic syndrome 
(28) and obese with fasting hyperliperlipidemia (24). In all three 
studies, the authors observed a decreased response of TGL after 
the OFLT with orlistat. The reduction of TGL was significantly cor-
related with decreased fasting TGL, insulin and HOMA after 12 
weeks or after 10 days of orlistat treatment.
TYPE 2 DIABETES MELLITUS
In two studies (22,23) TGL lower postprandial response is 
observed with administration of orlistat. Postprandial FFA response 
Table III. Summary of results of single dose of orlistat studies
Author
Patients, 
fats, Jadad 
score
TGL FFA VLDL HDL LDL TC RLP-C Glucose Insulin C-Peptide GLP-1
Sutter (18) 10 healthy 
OFLT fats: 1 vs. 
0.67g/kg
Jadad score: 4
Shorter
Reduction 
AUC
ns Smaller 
size
Smaller 
decrease in 
small HDL
Smaller 
increase in 
intermediate 
HDL
- - - ns ns - -
Gabriel (19) 31 healthy 
OFLT Fats: 50%
Jadad score: 3
Lower - Lower ns Lower Lower - - - - -
Abejuela (20) 27 healthy 
OFLT fats: 50%
Jadad score: 0
Lower - - Lower Lover Lower - - - - -
Cintora (21) 33 overweight 
obese.
OFLT fats: 53 g
Jadad score: 0
Atenuated 
AUC and 
peak at 
4 h
- - - - - - - - - -
Tan (22) 63 T2DM
OFLT fats: 70 g
Jadad score: 4
Lower at 
2 h
Lower 
at 
2 h
- - - ns Lower 
peak 
and 
AUC
- - - -
Damci (23) 29 T2DM 
OFLT fats: 25 g
Jadad score: 3
Attenuated ns - - - - - Attenuated ns Enhanced Enhanced
Reitsma (24) 17 
hyperlipidemic
OFLT fats: 50 
g/m2 
Jadad score: 4
Attenuated - - - - - - - - - -
TC: Total cholesterol, TGL: Triglyceride, LDL: Low density lipoproteins, HDL: High density lipoproteins, VLDL: Very low density lipoproteins, RLP-C: Remnant like particles cholesterol, AUC: Area 
under the curve, OFLT: oral fat loading test, T2DM: Diabetes mellitus type 2, Jadad score (17).
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in a paper is lower (22) whereas in the other it is not significant 
(23). Tan et al. (22) describe lower peak and AUC of remnant like 
particles cholesterol. Damci et al. (23) showed attenuated glucose 
response with enhanced C-peptide and GLP-1 response.
DISCUSSION
Orlistat is a synthetic hydrogenated derivative of lipstatin that 
partially inhibits gastric lipase, pancreatic lipase and carboxyl ester 
lipase enzymes. It reduces the absorption of ingested fat by 30%, 
increasing its excretion in the feces.
The European Medicines Agency (29) and the American FDA (30) 
approved its use only as a prescription agent for long-term weight 
loss in adults with a BMI > 30 kg/m2 or a BMI > 27 kg/m2, with 
comorbidities and in conjunction with a reduced-calorie diet.
Therefore, orlistat could improve lipid metabolism, ameliorat-
ing postprandial TGL increase and fasting LDL cholesterol levels. 
Thus, orlistat may represent another relatively unexplored phar-
macological approach to cardiovascular risk pathologies (31).
EFFECT ON TRIGLYCERIDES
Our systematic review suggests that orlistat can help to reduce 
PHTGL in obese, dislipemic and type 2 diabetic patients. In our revision, 
we have identified nine out of a total of eleven studies where orlistat 
attenuates postprandial TGL response to an OFLT. Only two studies 
(25,26) did not find significant results. One possible reason could be 
that individuals studied were normolipemic, so the increase after OFLT 
was too small to detect statistical significant differences. Furthermore, 
in these two studies orlistat treatment was prescribed before the OFLT 
(during ten days) and this could have attenuated the effect.
PHTGL may contribute to the increased risk of cardiovascular 
disease since there is evidence that accumulation of the rem-
nant particles is highly atherogenic (2,3). In addition, there is a 
weight-independent reduction in LDL-cholesterol in patients using 
orlistat, and it could be a good alternative for patients that do not 
tolerate statins (32). Hutton and Fergusson (33) reviewed 28 RCTs 
comparing orlistat to placebo during 6 months. The data showed a 
significant decrease in total cholesterol and LDL cholesterol with 
smaller decreases in serum TGL and HDL cholesterol.
Reitsma et al. (24) presented the first study about the effect 
of orlistat on OFLT, and speculated that the minor absorption of 
dietary fat with orlistat leads to a decreased formation of chylomi-
crons and chylomicron-remnants. The reason for the underlying 
mechanism could be that they are removed from circulation by the 
liver using the LDL receptor. Reduction in dietary fat absorption by 
orlistat may decrease the flux of cholesterol and TGL particles in 
the liver, resulting in the upregulation of hepatic LDL (34). Chylo-
micron-remnants are rich in cholesterol but poor in TGL, and that 
means a possible role in the process of atherogenesis.
Table IV. Summary of results of studies after sort treatment of orlistat
Author Patients/duration/fats/Jadad score TGL FFA VLDL HDL LDL TC Glucose Insulin
Shepard (25)
24 healthy male
10 days
OFLT Fats: 28 g
Jadad score: 4
ns ns ns ns ns - - -
Di Somma (26)
22 obese postmenopausal normolipemic
10 days.
OFLT Fats: 60 g
Jadad score: 2
ns Lower - Lower Lower Lower ns Lower
Turker (27)
26 obese female normolipemic with PPL
12 weeks 
OFLT Fats: 60 g/m2
Jadad score: 2
Lower - - ns ns ns - -
Tzotzas (28)
32 obese, metabolic syndrome
10 days
OFLT fats: 29% low caloric diet
Jadad score: 2
Lower - - - - - - -
Reitsma (24)
17 hyperlipidemic
8 weeks
OFLT fats: 50 g/m2 
Jadad score: 2
Lower - - - - - - -
TC: total cholesterol, TGL: Triglyceride, LDL: Low density lipoproteins, VLDL: Very low density lipoproteins, FFA: Free fatty acids, TGL-AUC: Area under the curve of 
triglycerides, OFLT: Oral fat loading test, PPL: Postprandial lipemia, Jadad score (17).
479THE EFFECT OF ORLISTAT ON POSTPRANDIAL HYPERTRIGLYCERIDEMIA BY ORAL FAT LOADING TEST.  
A SYSTEMATIC REVIEW
[Nutr Hosp 2016;33(2):472-481]
Later, others authors (18-20) showed similar results in healthy 
volunteers. They studied other steps of the TGL metabolism. Suter 
et al. (18) evaluated the effect of orlistat on postprandial lipemia 
and lipoprotein particle subclass after the ingestion of moder-
ate and high-fat meals in healthy volunteers. Mean change in 
large VLDL subclass concentration and mean VLDL size were 
significantly lower with orlistat. Large VLDL particles are pref-
erentially metabolized to small, dense LDL particles which may 
have an increased atherosclerotic potential (37). But Suter et al. 
(18) were not able to discriminate between intestinal chylomicrons 
and hepatic VLDL. In two studies with Philippine healthy volunteers 
(19,20), orlistat abolished postprandial peak of TGL and VLDL after 
a single high-fat meal. 
In a study with type 2 diabetic patients, Tan et al. (22) dis-
covered a significant acute effect of a single dose of orlistat on 
remnant-like particles of cholesterol. PHTGL is an inherent feature 
of diabetic dyslipidemia, and is frequently found even in diabetic 
patients with normal fasting triglyceride due to the long residence 
time of chylomicron and VLDL remnants in circulation (38). Triglyc-
eride-rich lipoprotein remnants are formed by lipoprotein lipase 
from intestinal chylomicrons in smaller and denser particles. 
These remnant particles are enriched in cholesteryl esters and 
poor in TGL. Some studies had shown that post-prandial changes 
in small remnant particles contribute to the severity of coronary 
heart disease in patients with type 2 diabetes mellitus (39,40).
EFFECT ON FREE FATTY ACIDS (FFA)
Tan et al. (22) also found a significant reduction in plasma FFA 
in patients with type 2 diabetes after treatment with orlistat which 
had not been previously reported. Di Somma et al. (26) observed 
the same results in obese patients with metabolic syndrome, but 
Sutter et al. (18), in healthy volunteers, and Damci et al. (23) did 
not find significant differences in type 2 diabetic patients.
Plasma FFA concentrations normally decrease in the early 
post-prandial period as the release of FFA from adipose tissue 
is suppressed by insulin and FFA derived from lipolysis of intes-
tinal triglyceride-rich lipoproteins are taken up by the liver and 
re-esterified into triglyceride. Patients with type 2 diabetes have 
higher fasting and postprandial FFA (41). Orlistat could reduce FFA 
possibly by the decreased formation of chylomicrons, but not all 
authors have found the same results.
EFFECT ON GLUCAGON-LIKE PEPTIDE-1 
(GLP-1) 
In obese type 2 diabetic patients, orlistat treatment is asso-
ciated with improved glycemic control in the long term (42) and 
also with a lower incidence of type 2 diabetes in individuals 
with prediabetes (16). The anti-hyperglycemic effect of orlistat 
has been attributed to weight loss associated with a decrease 
in insulin resistance. However, the improvement in postprandial 
glucose levels with orlistat could be related to the improvement 
of postprandial secretion of certain incretins, such as GLP-1, due 
to increased delivery of fats to the distal ileum. An increase of 
GLP-1 mediated by orlistat could lead to suppressed appetite and 
improvement in meal-stimulated insulin release. 
However, in type 2 diabetic patients we have found three studies 
with conflicting results over the immediate effect of orlistat on the 
postprandial GLP-1 response. Damci et al. (23) found that a single 
dose of orlistat significantly enhanced the postprandial increase 
in GLP-1 and C-peptide levels and attenuated the postprandial 
rise in glucose and triglycerides in 29 type 2 diabetic patients. 
Pilichiewicz et al. (43) studied, in 7 subjects with type 2 diabetes 
mellitus, the effect of adding orlistat to a liquid meal containing oil 
and glucose consumed in the left lateral decubitus position. They 
found that orlistat potentiates postprandial rises in plasma insulin 
but attenuates plasma GLP-1 and glucose-dependent insulinotropic 
polypeptide (GIP) responses. Later, the same group presented anoth-
er study with 8 type 2 diabetic patients (44), and they once more 
discovered that the inhibition of fat absorption by orlistat results in 
a more rapid gastric emptying and a diminished GLP-1 response. 
The same group of healthy volunteers (45) showed that the 
increase in GLP-1 concentrations following a duodenal fat infusion 
is abolished by lipase inhibition with orlistat. 
Sahin et al. (46) found in 16 obese non-diabetic patients that 
orlistat had no significant effect on postprandial GLP-1, glucose 
or insulin levels after a mixed meal, although GLP-1 and insulin 
peaks were delayed into the second postprandial hour after treat-
ment with orlistat.
These contradictions regarding results could be explained 
by various factors like short life of plasma insulin or GLP-1, 
different type of hypoglycemic treatments or amount of fat in 
the OFLT. Furthermore, Beyson et al. (47) demonstrated differ-
ential stimulation of GLP-1 release by different types of oral fat 
(monounsaturated, olive oil; polyunsaturated, safflower oil; sat-
urated, palm stearin). The failure to get this effect with statistical 
significance may be due to the fact that there was only a single 
postprandial sampling of blood in these studies (23,43-46). 
In a repetitive administration of orlistat over a 10 day period, 
Di Somma et al. (26) found lower postprandial levels of plasmatic 
insulin in OFLT with orlistat, but they did not study GLP-1 levels. 
In our opinion, the results of Damci et al. (23) are more convincing 
because plasma half-life of C-peptide is 30 minutes, whereas 
insulin half-life is about 5 minutes.
EFFECT ON GASTRIC EMPTYING
On the other hand, orlistat has been reported to induce accelerated 
gastric emptying of fat and glucose, as O’Donovan studies (43-45) 
and other groups have demonstrated (48,49). Moreover, the lack of 
pancreatic lipase activity in cystic fibrosis with exocrine insufficiency 
results in an acceleration of gastric emptying due to a reduction in 
feedback inhibition from lipolytic products in the small intestine (50). 
Gastric emptying accounts for approximately 35% of the variance 
in initial postprandial blood glucose concentrations after a 75 g oral 
glucose load in both healthy subjects (51) and type 2 diabetes (52). 
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EFFECT ON FASTING NORMOLIPEMIA  
AND PHTGL PATIENTS
There are patients with fasting normolipemia and PHTGL. Its 
prevalence has not been established but it is associated with met-
abolic syndrome components, like androgen obesity, dislipemia 
and insulin resistance. This kind of patients could represent the 
main target of therapy with orlistat. Turker et al. (27) found, in fast-
ing normolipidemic obese women and PHTGL, that 12 weeks of 
treatment with orlistat plus a low calories diet was associated with 
a reduction in postprandial TGL, independent of reductions from 
baseline in weight, waist circumference and insulin resistance.
The prescription label of orlistat establishes that the pharmaco-
logic effect of the drug is observed within 24-48 hours based on 
the amount of fecal fat excreted (35,36). We have identified in this 
systematic review 7 papers (18,24) that studied the acute effect of 
a single dose of orlistat on OFLT. It is important to note this fast effect 
because it is an expensive treatment and this test could select the 
responders’ patients. OFLT is a test that examines responses to high-
fat meal consumption (53) and it is indicated to diagnose PHTGL, in 
the same way that an oral glucose tolerance test is used for diabe-
tes diagnosis. The association of orlistat to OFLT could offer double 
interest: diagnosis of PHTGL and orlistat potency in each patient.
Our present review presents several methodological limitations 
because of the heterogeneity of the studies. The absence of stand-
ardization of OFLT is the most important problem regarding its general 
use. Castro-Cabezas et al. (54) have proposed the autodetermination 
of diurnal capillary TGL after each meal. Moreover, non-fasting TGL has 
been used for screening and management of elevated levels of TGL 
in recent major guidelines (10,11). Secondly, the majority of the study 
presents a very small number of patients, so their results can only sug-
gest tendencies. Thirdly, there is a very low number of studies for each 
group of patients, which are joined to the small number of patients in 
each study, making it impossible to perform a meta-analysis.
CONCLUSION
Despite these limitations, we can conclude that the positive and 
consistent findings of the included studies suggest that orlistat 
can help to reduce postprandial plasmatic triglyceride, especially 
in patients with postprandial hypertriglyceridemia related to obe-
sity, dyslipidemia or type-2 diabetes.
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